Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Divalproex Sodium
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alembic Pharma Gets USFDA Nod for Seizure Treatment Drug
Details : Divalproex sodium is an GABA stimulating, anti-epileptic drug indicated for monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures.
Product Name : Depakote Sprinkle-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2024
Lead Product(s) : Divalproex Sodium
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Divalproex Sodium,Sodium Valproate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cereno's HDAC Inhibitor Reduces Risks from PAH in Phase 2 Trial
Details : CS1 is an HDAC inhibitor that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for pulmonary arterial hypertension.
Product Name : CS1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2024
Lead Product(s) : Divalproex Sodium,Sodium Valproate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Divalproex Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH.
Product Name : CS1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2021
Lead Product(s) : Divalproex Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable